Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels

References

• Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304–1313
   PubMed Web of Science ®Google Scholar
• Witko V, Nguyen AT, Descamps-Latscha B. Microtiter plate assay for phagocyte-derived taurine-chloramines. J Clin Lab Anal 1992; 6: 47–53
   PubMed Web of Science ®Google Scholar
• Capeillère-Blandin C, Gausson V, Descamps-Latscha B, Witko-Sarsat V. Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim Biophys Acta 2004; 1689: 91–102
   PubMed Web of Science ®Google Scholar
• Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002; 162: 221–225
   PubMed Web of Science ®Google Scholar
• Buonocore G, Perrone S, Longini M, Terzuoli L, Bracci R. Total hydroperoxide and advanced oxidation protein products in preterm hypoxic babies. Pediatr Res 2000; 47: 221–224
   PubMed Web of Science ®Google Scholar
• Buonocore G, Perrone S, Longini M, Vezzosi P, Marzocchi B, Paffetti P, Bracci R. Oxidative stress in preterm neonates at birth and on the seventh day of life. Pediatr Res 2002; 52: 46–49
   PubMed Web of Science ®Google Scholar
• Kalousova M, Skrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002; 51: 597–604
   PubMed Web of Science ®Google Scholar
• Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003; 34: 1563–1574
   PubMed Web of Science ®Google Scholar
• Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med 2004; 116: 595–600
   PubMed Web of Science ®Google Scholar
• Yazici C, Köse K, Calis M, Kuzugüden S, Kirnap M. Protein oxidation status in patients with ankylosing spondylitis. Rheumatology (Oxford) 2004; 43: 1235–1239
   PubMed Web of Science ®Google Scholar
• Selmeci L, Seres L, Antal M, Lukács J, Regöly-Mérei A, Acsády G. Advanced oxidation protein products (AOPP) for monitoring oxidative stress in critically ill patients: A simple, fast and inexpensive automated technique. Clin Chem Lab Med 2005; 43: 294–297
   PubMed Web of Science ®Google Scholar
• Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, Cardoso C, Noël LH, Guérin AP, London GM, Jungers P. Early prediction of IgA nephropathy progression: Proteinuria and AOPP are strong prognostic markers. Kidney Int 2004; 66: 1606–1612
   PubMed Web of Science ®Google Scholar
• Collen D, Tytgat GN, Claeys H, Piessens R. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. Br J Hematol 1972; 22: 681–700
   PubMedGoogle Scholar
• Upchurch GR, Jr, Ramdev N, Walsh MT, Loscalzo J. Prothrombotic consequences of the oxidation of fibrinogen and their inhibition by aspirin. J Thromb Thrombolysis 1998; 5: 9–14
   PubMed Web of Science ®Google Scholar
• Belisario MA, Di Domenico C, Pelagalli A, Della Morte R, Staiano N. Metal-ion catalyzed oxidation affects fibrinogen activity on platelet aggregation and adhesion. Biochimie 1997; 79: 449–455
   PubMedGoogle Scholar
• Shacter E, Williams JA, Lim M, Levine RL. Differential susceptibility of plasma proteins to oxidative modification: Examination by western blot immunoassay. Free Radic Biol Med 1994; 17: 429–437
   PubMed Web of Science ®Google Scholar
• Shacter E, Williams JA, Levine RL. Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation. Free Radic Biol Med 1995; 18: 815–821
   PubMed Web of Science ®Google Scholar
• Michelis R, Gery R, Sela S, Shurtz-Swirsky R, Grinberg N, Snitkovski T, Shasha SM, Kristal B. Carbonyl stress induced by intravenous iron during hemodialysis. Nephrol Dial Transplant 2003; 18: 924–930
   PubMedGoogle Scholar
• Pignatelli B, Li CQ, Boffetta P, Chen Q, Ahrens W, Nyberg F, Mukeria A, Bruske-Hohlfeld I, Fortes C, Constantinescu V, Ischiropoulos H, Ohshima H. Nitrated and oxidized plasma proteins in smokers and lung cancer patients. Cancer Res 2001; 61: 778–784
   PubMed Web of Science ®Google Scholar
• Himmelfarb J, McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001; 60: 358–363
   PubMed Web of Science ®Google Scholar
• Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Rad Biol Med 2000; 28: 1717–1725
   PubMed Web of Science ®Google Scholar
• Korte W, Riesen WF. Comparability of serum and plasma concentrations of haemostasis activation markers. Clin Chem Lab Med 2001; 39: 627–630
   PubMedGoogle Scholar
• Park CT, Wright SD. Fibrinogen is a component of a novel lipoprotein particle: Factor H-related protein (FHRP)-associated lipoprotein particle (FALP). Blood 2000; 95: 198–204
   PubMedGoogle Scholar
• Doolittle RF. The evolution of vertebrate fibrinogen. Fed Proc 1976; 35: 2145–2149
   PubMedGoogle Scholar
• Zhang SM, Loker ES. Representation of an immune responsive gene family encoding fibrinogen-related proteins in the freshwater mollusc Biomphalaria glabrata, an intermediate host for Schistosoma mansoni. Gene 2004; 341: 255–266
   PubMed Web of Science ®Google Scholar
• Kamath S, Lip GY. Fibrinogen: Biochemistry, epidemiology and determinants. QJM 2003; 96: 711–729
   PubMed Web of Science ®Google Scholar
• Koenig W. Fibrin(ogen) in cardiovascular disease: An update. Thromb Haemost 2003; 89: 601–609
   PubMed Web of Science ®Google Scholar
• Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003; 169: 203–214
   PubMed Web of Science ®Google Scholar
• Hansson GK. Mechanisms of disease: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685–1695
   PubMed Web of Science ®Google Scholar
• Vadseth C, Souza JM, Thomson L, Seagraves A, Nagaswami C, Scheiner T, Torbet J, Vilaire G, Bennett JS, Murciano JC, Muzykantov V, Penn MS, Hazen SL, Weisel JW, Ischiropoulos H. Pro-thrombotic state induced by post-translational modification of fibrinogen by reactive nitrogen species. J Biol Chem 2004; 279: 8820–8826
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 1102–1111
   PubMed Web of Science ®Google Scholar
• Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson V, Mothu N, London GM, Jungers P. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005; 45: 39–47
   PubMed Web of Science ®Google Scholar
• Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005; 25: 279–286
   PubMed Web of Science ®Google Scholar
• Davies MJ. The oxidative environment and protein damage. Biochim Biophys Acta 2005; 1703: 93–109
   PubMed Web of Science ®Google Scholar